share_log

歌禮製藥-B:翌日披露報表

ASCLETIS-B: Next Day Disclosure Return

香港交易所 ·  Jan 29 04:58
Summary by Moomoo AI
歌禮製藥有限公司於2024年1月29日提交了翌日披露報表,披露了自2023年12月19日至2024年1月29日期間的股份購回活動。該公司在此期間共購回股份達60,121,000股,佔已發行股份的5.5302%。最後一次購回發生在2024年1月29日,當日購回1,500,000股,每股價格介於HKD 1.64至HKD 1.74之間,總付出金額為HKD 2,537,730。根據報表,歌禮製藥確認所有購回活動均獲得董事會正式授權批准,並符合香港聯合交易所有限公司證券上市規則的相關規定。
歌禮製藥有限公司於2024年1月29日提交了翌日披露報表,披露了自2023年12月19日至2024年1月29日期間的股份購回活動。該公司在此期間共購回股份達60,121,000股,佔已發行股份的5.5302%。最後一次購回發生在2024年1月29日,當日購回1,500,000股,每股價格介於HKD 1.64至HKD 1.74之間,總付出金額為HKD 2,537,730。根據報表,歌禮製藥確認所有購回活動均獲得董事會正式授權批准,並符合香港聯合交易所有限公司證券上市規則的相關規定。
Song Pharmaceutical Co., Ltd. filed a Next Day Disclosure Report on January 29, 2024, disclosing its share repurchase activities for the period from December 19, 2023 to January 29, 2024. During this period, the company repurchased 60,121,000 shares, representing 5.5302% of the issued shares. The last repurchase took place on 29 January 2024 and repurchased 1,500,000 shares at a price of HKD 1.64 to HKD 1.74 per share for a total payout of HKD 2,537,730. According to the report, Song Pharmaceuticals confirmed that all repurchases have been formally authorized by the Board of Directors and comply with the relevant provisions of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
Song Pharmaceutical Co., Ltd. filed a Next Day Disclosure Report on January 29, 2024, disclosing its share repurchase activities for the period from December 19, 2023 to January 29, 2024. During this period, the company repurchased 60,121,000 shares, representing 5.5302% of the issued shares. The last repurchase took place on 29 January 2024 and repurchased 1,500,000 shares at a price of HKD 1.64 to HKD 1.74 per share for a total payout of HKD 2,537,730. According to the report, Song Pharmaceuticals confirmed that all repurchases have been formally authorized by the Board of Directors and comply with the relevant provisions of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more